Olopatadine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Olopatadine: From Allergic Rhinitis to Rosacea Conjunctivitis
One-Sentence Summary
Olopatadine was originally used to treat allergic conditions of the nose and eyes, such as allergic rhinitis and allergic, atopic, vernal and papillary conjunctivitis. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis (also vasomotor rhinitis, atopic conjunctivitis, papillary conjunctivitis, vernal conjunctivitis) |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 12 authorizations in total (1 NDA, 11 ANDAs), all cancelled |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, olopatadine is a histamine H1 receptor antagonist and mast cell stabilizer, and its efficacy in allergic eye and nose conditions is established.
Rosacea-associated conjunctivitis is driven mainly by meibomian gland dysfunction, tear film instability, and inflammation (for example IL-1, matrix metalloproteinases, Demodex mites and microbial factors), rather than primarily by histamine-mediated mast cell activation. A plausible link is shared ocular surface inflammation and possible mast cell involvement, which might relieve itching or redness.
This link is hypothetical and is not supported by the data compiled for this report. The very high TxGNN score (99.41%) is a computational prediction only and is not evidence of clinical efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
All 12 authorizations are cancelled; none is currently valid. Approved indication text is not available for these records. Five of the 12 are listed below.
| Authorization Number | Product Name | Dosage Form | Status |
|---|---|---|---|
| NDA020688 | PATADAY TWICE A DAY RELIEF (Alcon Laboratories) | Solution | Cancelled |
| ANDA219557 | Olopatadine Hydrochloride (Glenmark Therapeutics) | Solution | Cancelled |
| ANDA209420 | Olopatadine Hydrochloride (Alembic Pharmaceuticals) | Solution/Drops | Cancelled |
| ANDA091572 | Olopatadine Hydrochloride (Apotex) | Metered spray | Cancelled |
| ANDA210901 | Olopatadine Hydrochloride (Amneal Pharmaceuticals) | Metered spray | Cancelled |
Safety Considerations
- Contraindications (from the knowledge graph, not label text): lower respiratory tract disease, paranasal sinus disease, nasal cavity disease, upper respiratory tract disease.
- Drug Interactions: 100 potential interactions were identified, but all main entries have an unspecified severity level. Examples include pantoprazole, doxycycline, clotrimazole, metformin, omeprazole, lansoprazole, cimetidine, triamcinolone, prednisone and simvastatin. Clinical significance cannot be judged from the available data.
Package insert warnings and contraindications were not available for this report; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no registered clinical trials or publications (Evidence Level L5). The proposed mechanism is hypothetical, because rosacea conjunctivitis is not primarily histamine-driven. All US authorizations are also cancelled, and package insert safety data are missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from FDA labelling (a blocking gap for safety screening)
- Detailed mechanism of action data (MOA) from DrugBank
- A literature and trial search for olopatadine in ocular rosacea or meibomian gland dysfunction
- Confirmation of the current US market and route availability for ophthalmic products
- Interaction severity levels for the key co-medications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.